TiGenix NV (NYSE Euronext: TIG) is a leading European cell therapy company with an advanced clinical stage pipeline of adult stem cell programmes, and a commercialised product.
The stem cell programmes are based on a validated platform of allogeneic expanded adipose-derived stem cells (eASCs) targeting autoimmune and inflammatory diseases. Built on solid pre-clinical and CMC packages, they are being developed in close consultation with the European Medicines Agency. CX601 is in Phase III to treat complex perianal fistulas in patients with Crohn’s disease. Cx611 has successfully concluded a Phase IIa trial in rheumatoid arthritis, and is now in development for early rheumatoid arthritis and for severe sepsis.
The company’s commercialised product, ChondroCelect®, for cartilage repair in the knee, was the first approved cell-based product in Europe, and is marketed and distributed by Swedish Orphan Biovitrum AB (‘Sobi’, NASDAQ OMX Stockholm: SOBI) and Finnish Red Cross Blood Service (FRCBS). TiGenix is based in Leuven, Belgium, and has operations in Madrid , Spain.
Cx611 Development Plan webcast presentation
30 June 2014
R&D Media Briefing,
30 June 2014
9th edition European Smallcap Event,
April 7-8, Paris, France
9th Annual World Stem Cell & Regenerative Medicine Congress
May 20-22, London, UK
BioEquity Europe 2014
May 21-22, Amsterdam, the Netherlands